Baidu
map

因不符合儿童防护规定,美国Sandoz公司自愿召回氯沙坦钾和依泽替米贝处方药瓶

2019-09-04 不详 MedSci原创

氯沙坦钾和依泽替米贝处方药瓶的自愿召回已在美国宣布,因为包装不具备儿童防护作用。

氯沙坦钾和依泽替米贝处方药瓶的自愿召回已在美国宣布,因为包装不具备儿童防护作用。

Sandoz宣布召回约636000单位的依泽替米贝10毫克片剂和氯沙坦钾50毫克片剂。只有2018年7月至2019年8月销售的特定批次才受到影响。

药物没有安全或质量问题,但瓶子不安全,不符合美国毒物预防包装法规定的规定,如果被儿童吞食则构成风险。

该制药公司表示,患者应继续按照指示服用药物,并联系Sandoz免费更换儿童防护瓶盖。

到目前为止,没有报告任何事故或伤害。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082289, encodeId=427a2082289f9, content=<a href='/topic/show?id=bc8b861412f' target=_blank style='color:#2F92EE;'>#自愿召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86141, encryptionId=bc8b861412f, topicName=自愿召回)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Sat Mar 07 12:52:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374395, encodeId=13a73e439544, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:37:12 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700935, encodeId=1f151e0093500, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 08 10:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489275, encodeId=973a14892e5fc, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Fri Sep 06 00:52:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082289, encodeId=427a2082289f9, content=<a href='/topic/show?id=bc8b861412f' target=_blank style='color:#2F92EE;'>#自愿召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86141, encryptionId=bc8b861412f, topicName=自愿召回)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Sat Mar 07 12:52:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374395, encodeId=13a73e439544, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:37:12 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700935, encodeId=1f151e0093500, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 08 10:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489275, encodeId=973a14892e5fc, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Fri Sep 06 00:52:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
    2019-10-25 147612bem32暂无昵称

    写的真好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2082289, encodeId=427a2082289f9, content=<a href='/topic/show?id=bc8b861412f' target=_blank style='color:#2F92EE;'>#自愿召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86141, encryptionId=bc8b861412f, topicName=自愿召回)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Sat Mar 07 12:52:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374395, encodeId=13a73e439544, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:37:12 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700935, encodeId=1f151e0093500, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 08 10:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489275, encodeId=973a14892e5fc, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Fri Sep 06 00:52:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082289, encodeId=427a2082289f9, content=<a href='/topic/show?id=bc8b861412f' target=_blank style='color:#2F92EE;'>#自愿召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86141, encryptionId=bc8b861412f, topicName=自愿召回)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f07c2500133, createdName=12498adam40暂无昵称, createdTime=Sat Mar 07 12:52:00 CST 2020, time=2020-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=374395, encodeId=13a73e439544, content=写的真好, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/21/e031c1d6c6115cbe1737b2149e602c1d.jpg, createdBy=3c105212218, createdName=147612bem32暂无昵称, createdTime=Fri Oct 25 10:37:12 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700935, encodeId=1f151e0093500, content=<a href='/topic/show?id=44d4641040e' target=_blank style='color:#2F92EE;'>#氯沙坦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64104, encryptionId=44d4641040e, topicName=氯沙坦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Mar 08 10:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489275, encodeId=973a14892e5fc, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Fri Sep 06 00:52:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map